

CONTRACT AMENDMENT NO. 3

On the testing of blood, plasma and serum samples

by and between

**Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha
U vojenské nemocnice 1200
CZ - 169 02 Praha 6**

represented by the director of the hospital

Prof. MUDr. Miroslav Zavoral, Ph. D.

– hereinafter referred to as "Partner" –

and

**Takeda Pharmaceuticals International AG
Thurgauerstrasse 130
CH-8152 Glattpark / Opfikon
Switzerland**

represented by the members of the management

Dr. René Büchel and Barbara Lenzlinger

– hereinafter referred to as "Takeda" –



Preamble


WHEREAS Baxalta GmbH has been merged into its parent company Takeda Pharmaceuticals International AG effective as of September 30, 2022 and Takeda Pharmaceuticals International AG has accepted and assumed all rights and obligations under the Agreement from Baxalta GmbH by universal succession.

The contractual parties have signed a testing contract on 02.07.2020 resp. 16.07.2020, effective date 16.07.2020 and valid until 31.12.2022. As well an amendment no. 1 (testing, price adaptation and prolongation 2023) came into force as of 01.01.2023 and an amendment no. 2 (data processing) came into force as of 01.06.2022.

This Amendment No. 3 amends Annex No. 1, which will be valid and effective in the version attached to this Amendment No. 3. At the same time, the validity of this contract will be extended until 31.12.2024.

An integral part of this Amendment No. 3 is Annex No. 1 - Price Agreement.

Příloha 1: Dohoda o ceně / Annex 1: Price Agreement



ANNEX 1

Plasma Procurement



Entry into force

This Contract Amendment no. 3 shall enter into force on the date of signature by both Contracting Parties and will become effective on 01.01.2024.

This amendment no. 3 shall be valid for the year 2024. All other provisions of the contract shall remain unaffected and in full force.

The contracting parties have agreed that this Amendment no. 3 will be sent to the administrator of the register of contracts for publication pursuant to Act No. 340/2015 Coll., on special conditions for the effectiveness of certain contracts, publication of these contracts and the register of contracts no later than 10 working days after the conclusion of this Amendment no. 3. The Contracting Parties shall indicate as their trade secrets, the protection of which they adequately ensure, the information contained in Annex no. 1 to this Amendment no. 3.

In Glattpark/Opfikon (date):

09.08.2023

Takeda Pharmaceuticals
International AG
Dr. René Büchel
Head 3rd Party Plasma Europe
Thurgauerstrasse 130
CH-8152 Opfikon (Glattpark)

← signature / stamp ⇒

[Redacted]

Dr. René Büchel

Takeda Pharmaceuticals International AG

In Praha (date):

[Redacted]

prof. MUDr.
Miroslav
Zavoral Ph.D.
Digitálně podepsal
prof. MUDr. Miroslav
Zavoral Ph.D.
Datum: 2023.08.01
13:12:29 +02'00'

Prof. MUDr. Miroslav Zavoral, Ph.D.

Ústřední vojenská nemocnice –
Vojenská fakultní nemocnice Praha

← signature / stamp

IV

[Redacted] / Deborah Hbbett

Takeda Pharmaceuticals International AG